Opinion: Pharma profiteering isn’t going away, and so we can’t either

At the height of the COVID-19 pandemic, while people in high-income countries were receiving booster shots, nurses in Africa were still waiting for their first. Moderna, Pfizer, and BioNTech were calling the shots — making $1,000 a second from vaccines that were developed with public money, building on years of work from scientists at public institutions. This vast power imbalance created nine new pharmaceutical billionaires in a matter of months, while many of the world’s poorest died without vaccines.

To the millions of people in the global south, the message was clear: When the chips are down, your lives are not as valued as those in high-income countries.

We saw this coming. We had both lived through the darkest days of the AIDS pandemic. We had seen the lives of relatives, friends, and colleagues taken because pharmaceutical monopolies meant lifesaving HIV/AIDS medicines cost thousands of dollars a month. We fought then, and we won; generic, HIV/AIDS drugs are now available to millions of the poorest people on earth.

This article is free to read - just register or sign in

Access news, newsletters, events and more.

Join us